Refractory inflammatory bowel disease |
| |
Authors: | Karl H Kim Gary R Lichtenstein |
| |
Institution: | (1) Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, 3400 Spruce Street, 3rd Floor Ravdin Building, 19104-4283 Philadelphia, PA, USA |
| |
Abstract: | Opinion statement Therapeutic options for refractory colonic inflammation in patients with ulcerative colitis or Crohn’s disease have recently
been expanded with the introduction of biologic therapies. Intravenous corticosteroids and cyclosporine A remain the standard
therapies for severe ulcerative colitis. Monoclonal antibodies directed at tumor necrosis factor-α have proven to be exceptionally
efficacious in patients with severe or refractory Crohn’s disease. Immunomodulatory therapy with azathioprine, 6-mercaptopurine,
or methotrexate has demonstrated efficacy for maintenance of remission in patients with refractory ulcerative colitis or Crohn’s
disease. The use of experimental biologic agents may be considered for those patients who fail to respond to or remain dependent
on corticosteroids. Surgical intervention still remains for patients with severe colitis who fail to respond to medical therapy
or develop life-threatening complications such as perforation or toxic megacolon. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|